Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate is used in respiratory therapy targeting the bronchial smooth‑muscle pathway to improve airflow.

• Asthma: improves long‑term control and reduces symptoms when used with inhaled corticosteroids.
• Chronic obstructive pulmonary disease (COPD): provides maintenance bronchodilation and helps reduce exacerbations.
• Exercise‑induced bronchoconstriction: offers rapid onset relief of bronchospasm during physical activity.

• Formoterol binds selectively to β2‑adrenergic receptors on airway smooth‑muscle cells, activating adenylate cyclase and increasing cyclic AMP levels. The rise in cAMP leads to relaxation of bronchial smooth muscle, producing sustained bronchodilation for up to 12 hours after inhalation.

Formoterol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Tremor: mild shaking of the hands.
• Headache: occasional mild to moderate headache.
• Throat irritation: sensation of dryness or irritation in the throat.
• Cough: transient cough after inhalation.
• Palpitations: awareness of heart beating faster than usual.
• Nervousness: mild feelings of anxiety or jitteriness.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing difficulty.
• Cardiac arrhythmia: irregular heart rhythm that may require medical attention.
• Hypokalemia: low blood potassium levels, potentially causing muscle weakness.
• Severe allergic reaction: rash, swelling, or difficulty breathing indicating anaphylaxis.

When using Oxis Turbuhaler, patients and healthcare providers should consider several safety measures.

• Assess asthma or COPD severity: confirm that maintenance therapy with a long‑acting β2‑agonist is appropriate.
• Review cardiovascular history: patients with arrhythmias or coronary disease need careful monitoring.
• Monitor for paradoxical bronchospasm: discontinue if breathing worsens after inhalation.
• Avoid abrupt discontinuation: tapering may be needed to prevent loss of bronchodilation.
• Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Formoterol may interact with other medications that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid)

• Non‑selective β‑blockers: may reduce bronchodilator effect and precipitate bronchospasm.
• Monoamine oxidase inhibitors (MAOIs): can increase risk of tachycardia and hypertension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypokalemia, requiring electrolyte monitoring.

• Theophylline: combined use can enhance cardiovascular stimulation.
• Anticholinergic bronchodilators: additive bronchodilation may increase risk of tachycardia.